Get the latest Science News and Discoveries
Insilico Medicine receives IND approval from FDA for novel MAT2A inhibitor ISM3412 - EurekAlert
Clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine (“Insilico”) announces that it has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ISM3412, a small molecule inhibitor of MAT2A for the potential treatment of MTAP deleted cancers designed with Insilico’s generative AI platform.
None
Or read this on Eureka Alert